journal article·2024-06Open access

Hepatocellular Carcinoma LINC01116 Outcompetes T Cells for Linoleic Acid and Accelerates Tumor Progression

Kun Ma, Junhui Chu, Yufeng Liu, Linmao Sun, Shuo Zhou, Xianying Li, Changyong Ji, Ning Zhang, Xinyu Guo, Shuhang Liang, Tianming Cui, Qingsong Hu, Jiabei Wang, Yao Liu, Lianxin Liu

Advanced Science· Volume 11· Issue 21

Abstract

Abstract Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with a highly immunosuppressive tumor microenvironment and a typical pattern of disturbances in hepatic lipid metabolism. Long non‐coding RNAs are shown to play an important role in the regulation of gene expression, but much remains unknown between tumor microenvironment and lipid metabolism as a bridging molecule. Here, long intergenic nonprotein coding RNA 01116 (LINC01116) acts as this molecular which is frequently upregulated in HCC patients and associated with HCC progression in vitro and in vivo is identified. Mechanistically, LINC01116 stabilizes EWS RNA‐binding protein 1 (EWSR1) by preventing RAD18 E3 Ubiquitin Protein Ligase (RAD18) ‐mediated ubiquitination. The enhanced EWSR1 protein upregulates peroxisome proliferator activated receptor alpha (PPARA) and fatty acid binding protein1 (FABP1) expression, a long‐chain fatty acid (LCFA) transporter, and thus cancer cells outcompete T cells for LCFAs, especially linoleic acid, for seeding their own growth, leading to T cell malfunction and HCC malignant progression. In a preclinical animal model, the blockade of LINC01116 leads to enhanced efficacy of anti‐PD1 treatment accompanied by increased cytotoxic T cell and decreased exhausted T cell infiltration. Collectively, LINC01116 is an immunometabolic lncRNA and the LINC01116‐EWSR1‐PPARA‐FABP1 axis may be targetable for cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · Peroxisome Proliferator-Activated Receptors · RNA modifications and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General Surgery Key Laboratory of Hepatosplenic Surgery Ministry of Education The First Affiliated Hospital of Harbin Medical University Harbin 150001 China

Department of Hepatobiliary Surgery Centre for Leading Medicine and Advanced Technologies of IHM The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui 230001 China

Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery Hefei Anhui 230001 China

Anhui Provincial Clinical Research Center for Hepatobiliary Diseases Hefei Anhui 230001 China

Department of Gastrointestinal Surgery Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui 230001 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Anhui Province

References (53)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1002/hep.3128810.1002/hep.31288 ↗
3. 10.1038/s41575-020-00395-010.1038/s41575-020-00395-0 ↗
4. 10.1016/j.canlet.2017.05.00210.1016/j.canlet.2017.05.002 ↗
5. 10.1084/jem.2020160610.1084/jem.20201606 ↗
6. 10.1016/j.tcb.2021.08.00210.1016/j.tcb.2021.08.002 ↗
7. 10.1038/nature2137910.1038/nature21379 ↗
8. 10.1038/nature0809710.1038/nature08097 ↗
9. 10.1016/j.canlet.2023.21626710.1016/j.canlet.2023.216267 ↗
10. 10.1016/j.cell.2015.10.06810.1016/j.cell.2015.10.068 ↗
11. 10.1016/j.immuni.2019.06.00210.1016/j.immuni.2019.06.002 ↗
12. 10.1016/j.immuni.2016.03.01610.1016/j.immuni.2016.03.016 ↗
13. 10.1016/j.immuni.2018.04.02210.1016/j.immuni.2018.04.022 ↗
14. 10.3390/cancers1205128410.3390/cancers12051284 ↗
15. 10.1038/s41467-019-14262-310.1038/s41467-019-14262-3 ↗
16. 10.1016/j.molmet.2016.04.00510.1016/j.molmet.2016.04.005 ↗
17. Jiang L. · Mol. Med. Rep. · 2021 · 23
18. 10.1186/s12967-021-02707-710.1186/s12967-021-02707-7 ↗
19. 10.1016/j.arcmed.2021.06.00810.1016/j.arcmed.2021.06.008 ↗
20. 10.3389/fcell.2021.73692710.3389/fcell.2021.736927 ↗
21. 10.1038/s41580-018-0085-z10.1038/s41580-018-0085-z ↗
22. 10.1038/nrm.2017.10410.1038/nrm.2017.104 ↗
23. 10.1002/path.244510.1002/path.2445 ↗
24. 10.1021/acschembio.5b0056610.1021/acschembio.5b00566 ↗
25. 10.15252/emmm.20191083510.15252/emmm.201910835 ↗
26. 10.1016/j.ymthe.2022.12.01310.1016/j.ymthe.2022.12.013 ↗
27. 10.1038/s41572-018-0003-x10.1038/s41572-018-0003-x ↗
28. 10.1111/cup.1387010.1111/cup.13870 ↗
29. 10.1016/j.bbadis.2018.10.04210.1016/j.bbadis.2018.10.042 ↗
30. 10.1016/j.ccell.2021.07.00310.1016/j.ccell.2021.07.003 ↗
31. 10.1080/21655979.2021.198284410.1080/21655979.2021.1982844 ↗
32. 10.1038/s41392-020-00450-x10.1038/s41392-020-00450-x ↗
33. 10.1194/jlr.R05670510.1194/jlr.R056705 ↗
34. 10.1002/hep.3253810.1002/hep.32538 ↗
35. 10.1016/j.cmet.2019.11.01010.1016/j.cmet.2019.11.010 ↗
36. 10.1021/acs.biochem.0c0047710.1021/acs.biochem.0c00477 ↗
37. 10.1016/j.jhep.2022.04.03810.1016/j.jhep.2022.04.038 ↗
38. 10.1186/s13045-021-01200-410.1186/s13045-021-01200-4 ↗
39. 10.1038/s41586-020-2682-110.1038/s41586-020-2682-1 ↗
40. 10.1038/s41584-019-0356-x10.1038/s41584-019-0356-x ↗
41. 10.1016/j.jhep.2023.01.01110.1016/j.jhep.2023.01.011 ↗
42. 10.1038/s41580-021-00447-610.1038/s41580-021-00447-6 ↗
43. 10.1093/bib/bbab50410.1093/bib/bbab504 ↗
44. Wang P. · Science · 2019 · 366
45. 10.1007/s12185-020-03027-010.1007/s12185-020-03027-0 ↗
46. 10.1016/j.humpath.2019.05.00110.1016/j.humpath.2019.05.001 ↗
47. 10.3390/diagnostics1106109310.3390/diagnostics11061093 ↗
48. 10.1016/j.path.2018.10.00710.1016/j.path.2018.10.007 ↗
49. 10.1038/s41575-020-00381-610.1038/s41575-020-00381-6 ↗
50. 10.1016/j.immuni.2014.12.03010.1016/j.immuni.2014.12.030 ↗
51. 10.1016/j.molcel.2020.09.00610.1016/j.molcel.2020.09.006 ↗
52. Thorsson V. · Immune Landscape Cancer. Immun · 2018 · 48
53. 10.1016/j.cell.2017.05.03510.1016/j.cell.2017.05.035 ↗